TIMP2 Gene Polymorphisms Are Associated with Hypertension in Patients with Myocardial Infarction
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Liu L, He D, Zhou W, Guo Z, Ma Y, Liu L Heliyon. 2024; 10(17):e36685.
PMID: 39286176 PMC: 11403484. DOI: 10.1016/j.heliyon.2024.e36685.
Butkiewicz D, Gdowicz-Klosok A, Krzesniak M, Rutkowski T, Lasut-Szyszka B, Skladowski K Cancers (Basel). 2022; 14(7).
PMID: 35406617 PMC: 8997703. DOI: 10.3390/cancers14071844.
Xu P, Guo W, Jin T, Wang J, Fan D, Hao Z Oncotarget. 2016; 8(1):1166-1176.
PMID: 27901480 PMC: 5352044. DOI: 10.18632/oncotarget.13590.
References
1.
Ban J, Yoon K, Kim S, Kang S, Chung J
. Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population. Pediatr Cardiol. 2008; 30(3):331-5.
DOI: 10.1007/s00246-008-9341-x.
View
2.
Newby A
. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2004; 85(1):1-31.
DOI: 10.1152/physrev.00048.2003.
View
3.
Chen Q, Lu L, Peng W, Hu J, Yan X, Wang L
. Polymorphisms of MMP-3 and TIMP-4 genes affect angiographic coronary plaque progression in non-diabetic and type 2 diabetic patients. Clin Chim Acta. 2009; 405(1-2):97-103.
DOI: 10.1016/j.cca.2009.04.007.
View
4.
Mermod N, Williams T, Tjian R
. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature. 1988; 332(6164):557-61.
DOI: 10.1038/332557a0.
View
5.
Hansson J, Vasan R, Arnlov J, Ingelsson E, Lind L, Larsson A
. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One. 2011; 6(1):e16185.
PMC: 3023803.
DOI: 10.1371/journal.pone.0016185.
View